10 largest shareholders per 30 December 2019:

  Number of Shares% of total
Sunstone Life Science Ventures Fund II K/S4,497,69919.1%
CMC SPV as of 3 April 20172,937,60612.5%
Øresund-Healthcare Capital K/S2,020,4908.6%
Alto invest1,175,1845.0%
Handelsbanken Småbolagsfond1,050,0004.5%
Fourth Swedish National Pension Fund (AP4)986,8414.2%
Styrelsen for Institutioner og Uddannelsesstøtte (SIU)512,0142.2%
Spogard Holding ApS 454,3881.9%
Helida Invest APS384,5011.6%
Alvina Invest ApS288,3771.2%
Other shareholders9,191,80839.1%


Our lead candidate Mangoral is a liver imaging drug (i.e. a liver specific contrast agent) being developed for detection and localization of potential liver metastases, using Magnetic Resonance Imaging (“MRI”) in patients where use of the current gold standard gadolinium-based contrast agents (“GBCAs”) may be medically inadvisable or cannot be administered. Mangoral is currently in Phase III clinical development.


Oncoral is a novel tablet-based formulation of the well-known chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric (stomach) cancer. Irinotecan is today mainly used for treating metastasized colorectal cancer. Although irinotecan is currently not approved for treating gastric cancer in the United States and in the EU, there is off-label use for this indication. Oncoral has completed Phase I studies with encouraging results and is ready for Phase II studies.


Ascelia has established a development program for lead candidate Mangoral, consisting of a pivotal Phase III efficacy study and two supportive studies. Mangoral started Phase III studies in beginning 2020. The clinical development strategy for Oncoral, Ascelia Pharma´s second drug candidate, is to obtain Phase II data and then to partner for the further development.